全文获取类型
收费全文 | 528篇 |
免费 | 25篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 29篇 |
妇产科学 | 1篇 |
基础医学 | 55篇 |
口腔科学 | 10篇 |
临床医学 | 23篇 |
内科学 | 109篇 |
皮肤病学 | 8篇 |
神经病学 | 6篇 |
特种医学 | 82篇 |
外科学 | 44篇 |
综合类 | 122篇 |
预防医学 | 15篇 |
眼科学 | 2篇 |
药学 | 13篇 |
肿瘤学 | 35篇 |
出版年
2021年 | 25篇 |
2020年 | 1篇 |
2019年 | 5篇 |
2018年 | 4篇 |
2017年 | 2篇 |
2016年 | 3篇 |
2015年 | 9篇 |
2014年 | 6篇 |
2013年 | 8篇 |
2012年 | 8篇 |
2011年 | 8篇 |
2010年 | 23篇 |
2009年 | 21篇 |
2008年 | 21篇 |
2007年 | 14篇 |
2006年 | 23篇 |
2005年 | 13篇 |
2004年 | 19篇 |
2003年 | 13篇 |
2002年 | 10篇 |
2001年 | 10篇 |
2000年 | 6篇 |
1999年 | 13篇 |
1998年 | 32篇 |
1997年 | 24篇 |
1996年 | 29篇 |
1995年 | 16篇 |
1994年 | 31篇 |
1993年 | 10篇 |
1992年 | 5篇 |
1991年 | 1篇 |
1990年 | 7篇 |
1989年 | 12篇 |
1988年 | 14篇 |
1987年 | 17篇 |
1986年 | 15篇 |
1985年 | 14篇 |
1984年 | 9篇 |
1983年 | 8篇 |
1982年 | 7篇 |
1981年 | 8篇 |
1980年 | 9篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1977年 | 4篇 |
1976年 | 4篇 |
1975年 | 4篇 |
1972年 | 1篇 |
1969年 | 1篇 |
1961年 | 1篇 |
排序方式: 共有555条查询结果,搜索用时 0 毫秒
101.
102.
103.
104.
105.
World Workshop on Oral Medicine VI: a systematic review of medication‐induced salivary gland dysfunction
下载免费PDF全文
![点击此处可从《Oral diseases》网站下载免费的PDF全文](/ch/ext_images/free.gif)
A Villa A Wolff N Narayana C Dawes DJ Aframian AM Lynge Pedersen A Vissink A Aliko YW Sia RK Joshi R McGowan SB Jensen AR Kerr J Ekström G Proctor 《Oral diseases》2016,22(5):365-382
The aim of this paper was to perform a systematic review of the pathogenesis of medication‐induced salivary gland dysfunction (MISGD). Review of the identified papers was based on the standards regarding the methodology for systematic reviews set forth by the World Workshop on Oral Medicine IV and the PRISMA statement. Eligible papers were assessed for both the degree and strength of relevance to the pathogenesis of MISGD as well as on the appropriateness of the study design and sample size. A total of 99 papers were retained for the final analysis. MISGD in human studies was generally reported as xerostomia (the sensation of oral dryness) without measurements of salivary secretion rate. Medications may act on the central nervous system (CNS) and/or at the neuroglandular junction on muscarinic, α‐and β‐adrenergic receptors and certain peptidergic receptors. The types of medications that were most commonly implicated for inducing salivary gland dysfunction were those acting on the nervous, cardiovascular, genitourinary, musculoskeletal, respiratory, and alimentary systems. Although many medications may affect the salivary flow rate and composition, most of the studies considered only xerostomia. Thus, further human studies are necessary to improve our understanding of the association between MISGD and the underlying pathophysiology. 相似文献
106.
107.
108.
阿魏酸钠对乙醇所致小鼠肝脏抗氧化功能改变的拮抗作用 总被引:19,自引:0,他引:19
研究了不同剂量乙醇对小鼠抗氧化和解毒功能的影响以及阿魏酸钠的拮抗作用。结果表明,大剂量乙醇(11.4g·kg-1ig)引起肝脏GSH-Px活性升高的同时,肝脏GSH-Re,SOD和GST活性降低,GSH耗竭,而血清GST升高;阿魏酸钠(100mg·kg-1ig,qd×10)预处理则明显拮抗大剂量乙醇所致的上述改变。表明阿魏酸钠对急性乙醇所致肝损害具有良好保护作用,其机理可能与提高GSH氧化还原酶功能、增加SOD活性和增强GSH结合反应有关。研究结果还提示,血清GST水平是反映乙醇性肝损害的灵敏指标。 相似文献
109.
AJ Wearden L Riste C Dowrick C Chew-Graham RP Bentall RK Morriss S Peters G Dunn G Richardson K Lovell P Powell 《BMC medicine》2006,4(1):1-12
Background
A major change has occurred in the last few years in the therapeutic approach to patients presenting with all forms of acute coronary syndromes. Whether or not these patients present initially to tertiary cardiac care centers, they are now routinely referred for early coronary angiography and increasingly undergo percutaneous revascularization. This practice is driven primarily by the angiographic image and technical feasibility. Concomitantly, there has been a decline in expectant or ischemia-guided medical management based on specific clinical presentation, response to initial treatment, and results of noninvasive stratification. This 'tertiarization' of acute coronary care has been fuelled by the increasing sophistication of the cardiac armamentarium, the peer-reviewed publication of clinical studies purporting to show the superiority of invasive cardiac interventions, and predominantly supporting (non-peer-reviewed) editorials, newsletters, and opinion pieces.Discussion
This review presents another perspective, based on a critical reexamination of the evidence. The topics addressed are: reperfusion treatment of ST-elevation myocardial infarction; the indications for invasive intervention following thrombolysis; the role of invasive management in non-ST-elevation myocardial infarction and unstable angina; and cost-effectiveness and real world considerations. A few cases encountered in recent practice in community and tertiary hospitals are presented for illustrative purposes The numerous and far-reaching scientific, economic, and philosophical implications that are a consequence of this marked change in clinical practice as well as healthcare, decisional and conflict of interest issues are explored.Summary
The weight of evidence does not support the contemporary unfocused broad use of invasive interventional procedures across the spectrum of acute coronary clinical presentations. Excessive and unselective recourse to these procedures has deleterious implications for the organization of cardiac health care and undesirable economic, scientific and intellectual consequences. It is suggested that there is need for a new equilibrium based on more refined clinical risk stratification in the treatment of patients who present with acute coronary syndromes. 相似文献110.
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811 总被引:23,自引:13,他引:23
Larson RA; Dodge RK; Burns CP; Lee EJ; Stone RM; Schulman P; Duggan D; Davey FR; Sobol RE; Frankel SR 《Blood》1995,85(8):2025-2037
The goal of this phase II multicenter clinical trial was to evaluate a new intensive chemotherapy program for adults with untreated acute lymphoblastic leukemia (ALL) and to examine prospectively the impact of clinical and biologic characteristics on the outcome. One hundred ninety-seven eligible and evaluable patients (16 to 80 years of age; median, 32 years of age) received cyclophosphamide, daunorubicin, vincristine, prednisone, and L-asparaginase; 167 patients (85%) achieved a complete remission (CR), 13 (7%) had refractory disease, and 17 (9%) died during induction. A higher CR rate was observed in younger patients (94% for those < 30 years old, 85% for those 30 to 59 years old, and 39% for those > or = 60 years old, P < .001) and in those who had a mediastinal mass (100%) or blasts with a T-cell immunophenotype. Eighty percent of B-lineage and 97% of T-cell ALL patients achieved a CR (P = .01). The coexpression of myeloid antigens did not affect the response rate or duration. Seventy percent of those with cytogenetic or molecular evidence of the Philadelphia (Ph) chromosome and 84% of those without such evidence achieved a CR (P = .11). Patients in remission received multiagent consolidation treatment, central nervous system prophylaxis, late intensification, and maintenance chemotherapy for a total of 24 months. After a median follow-up time of 43 months, the median survival for all 197 patients is 36 months; the median remission duration for the 167 CR patients is 29 months. Favorable pretreatment characteristics relative to remission duration or survival are younger age, the presence of a mediastinal mass or lymphadenopathy, a white blood cell count (WBC) less than 30,000/microL, L1 morphology, T or TMy immunophenotype, and the absence of the Ph chromosome. The estimates of the proportion surviving at 3 years are 69% for patients less than 30 years old, 39% for those 30 to 59 years old, 89% for those who had a mediastinal mass, 59% with WBC less than 30,000/microL, 63% with L1 morphology, 69% for T or TMy antigen expression, and 62% for those who lack the Ph chromosome. Fifteen patients (8%) had no unfavorable prognostic factors and have an estimated probability of survival at 5 years of 100% (95% confidence interval, 77% to 100%). This intensive chemotherapy regimen produces a high remission rate and a high proportion of durable remissions in adults with ALL. 相似文献